

Peer-Reviewed Publications:

1. O'Callaghan, J.P. and Holtzman, S.G.: Quantification of the analgesic activity of narcotic antagonists by a modified hot-plate procedure. *J. Pharmacol. Exp. Ther.* 192: 497-505, 1975.
2. O'Callaghan, J.P. and Holtzman, S.G.: Prenatal administration of morphine to the rat: Tolerance to the analgesic effect of morphine in the offspring. *J. Pharmacol. Exp. Ther.* 197: 533-544, 1976.
3. O'Callaghan, J.P. and Holtzman, S.G.: Prenatal Administration of levorphanol or dextrorphan to the rat: Analgesic effect of morphine in the offspring. *J. Pharmacol. Exp. Ther.* 200: 255-262, 1977.
4. O'Callaghan, J.P., Williams, N. and Clouet, D.H.: The effect of morphine on the endogenous phosphorylation of synaptic plasma membrane proteins of rat striatum. *J. Pharmacol. Exp. Ther.* 208: 96-105, 1979.
5. O'Callaghan, J.P., Chess, Q., McKimmey, C., and Clouet, D.H.: The Effects of opiates on the levels of cyclic 3'5'- guanosine monophosphate in discrete areas of the rat central nervous system. *J. Pharmacol. Exp. Ther.* 210: 361-367, 1979.
6. O'Callaghan, J.P., Juskevich, J.C. and Lovenberg, W.: Stimulation of synaptic membrane phosphorylation by a calcium and calmodulin independent heat stable cytosol factor. *Biochem. Biophys. Res. Comm.* 95: 82-89, 1980.
7. Kuhn, D.M., O'Callaghan, J.P. and Lovenberg, W.: The role of calmodulin in the activation of tryptophan hydroxylase by phosphorylating conditions. *Ann. N.Y. Acad. Sci.* 356: 399, 1980.
8. O'Callaghan, J.P., Dunn, L.A. and Lovenberg, W.: Calmodulin-mediated phosphorylation of synaptosomal cytosolic proteins. *Annals. N.Y. Acad. Sci.* 356: 417-421, 1980.
9. Kuhn, D.M., O'Callaghan, J.P., Juskevich, J. and Lovenberg, W.: Activation of brain tryptophan hydroxylase by ATP- Mg⁺⁺: Dependence on calmodulin. *Proc. Natl. Acad. Sci. USA* 77: 4688-4691, 1980.
10. O'Callaghan, J.P., Dunn, L.A. and Lovenberg, W.: Calcium-regulated phosphorylation in synaptosomal cytosol: Dependence on calmodulin. *Proc. Natl. Acad. Sci. USA.* 77: 5812-5816, 1980.
11. O'Callaghan, J.P., Juskevich, J.C. and Lovenberg, W.: The effects of morphine on calcium-regulated phosphorylation of synaptosomal cytosolic proteins from rat striatum. *J. Pharmacol. Exp. Ther.* 220: 696-702, 1982.
12. O'Callaghan, J.P., Miller, D.B. and Reiter, L.W.: Acute postnatal exposure to triethyltin in the rat: Effects on specific protein composition of subcellular fractions from developing and adult brain. *J. Pharmacol. Exp. Ther.* 224: 466-472, 1983.
13. Patton, S.E., O'Callaghan, J.P., Miller, D.B. and Abou-Donia, M.B.: The effect of oral administration of tri-*o*-cresyl phosphate on *in vitro* phosphorylation of membrane and cytosolic proteins from chicken brain. *J. Neurochem.* 41: 897-901, 1983.
14. O'Callaghan, J.P. and Miller, D.B.: Nervous-system specific proteins as biochemical indicators of neurotoxicity. *Trends in Pharmacological Sciences.* 4: 388-390, 1983.

15. O'Callaghan, J.P., Lavin, K.L., Chess, Q. and Clouet, D.H.: A method for dissection of discrete regions of rat brain following microwave irradiation. *Brain Res. Bull.* 11: 31-42, 1983.
16. Cook, L.L., Heath, S.M. and O'Callaghan, J.P.: Distribution of tin in brain subcellular fractions following the administration of trimethyltin and triethyltin to the rat. *Toxicol. Appl. Pharmacol.* 73: 564-568, 1984.
17. O'Callaghan, J.P. and Miller, D.B.: Neuron-specific phosphoproteins as biochemical indicators of neurotoxicity: effects of acute administration of trimethyltin to the adult rat. *J. Pharmacol. Exp. Ther.* 231: 736-743, 1984.
18. Miller, D.B. and O'Callaghan, J.P.: Biochemical, functional and morphological indicators of neurotoxicity: effects of acute administration of trimethyltin to the developing rat. *J. Pharmacol. Exp. Ther.* 231: 744-751, 1984.
19. Patton, S.E., Lapadula, D.M., O'Callaghan, J.P., Miller, D.B. and Abou-Donia, M.B.: Changes in *in vitro* brain and spinal cord protein phosphorylation after a single oral administration of tri-*o*-cresyl phosphate to hens. *J. Neurochem.* 45: 1567-1577, 1985.
20. O'Callaghan, J.P. and Miller, D.B.: Cerebellar hypoplasia in the Gunn rat is associated with quantitative changes in neurotypic and gliotypic proteins. *J. Pharmacol. Exp. Ther.* 234: 522-533, 1985.
21. O'Callaghan, J.P. and Miller, D.B.: Diethyldithiocarbamate increases distribution of cadmium to brain but prevents cadmium-induced neurotoxicity. *Brain Res.* 370: 354-358, 1986.
22. Brock, T.O. and O'Callaghan, J.P.: Quantitative changes in the synaptic vesicle proteins, synapsin I and p38, and the astrocyte specific protein, GFAP, are associated with chemical-induced injury to the rat central nervous system. *J. Neurosci.* 7: 931-942, 1987.
23. Miller, D.B., Blackman, C.F. and O'Callaghan, J.P.: An increase in glial fibrillary acidic protein follows brain hyperthermia in rats. *Brain Res.* 415: 371-374, 1987.
24. O'Callaghan, J.P.: Cell-specific proteins as indicators of metal neurotoxicity. *Fundam. Appl. Toxicol.* 9: 613-615, 1987.
25. O'Callaghan, J.P. and Miller, D.B.: Acute exposure of the neonatal rat to triethyltin results in persistent changes in neurotypic and gliotypic proteins. *J. Pharmacol. Exp. Ther.* 244: 368-378, 1988.
26. Balaban, C.D., O'Callaghan, J.P. and Billingsley, M.L.: Trimethyl-tin-induced neuronal damage in the rat brain: Comparative studies using silver degeneration stains, immunocytochemistry and immunoassay for neurotypic and gliotypic proteins. *Neuroscience* 26: 337-361, 1988.
27. O'Callaghan, J.P. and Miller, D.B.: Acute exposure of the neonatal rat to tributyltin results in decreases in biochemical indicators of synaptogenesis and myelinogenesis. *J. Pharmacol. Exp. Ther.* 246: 394-402, 1988.
28. Reinhard, J.F., Jr., Miller, D.B. and O'Callaghan, J.P.: The neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) increases glial fibrillary acidic protein and decreases dopamine levels of the mouse striatum: Evidence for glial response to injury. *Neurosci. Lett.* 95: 246-251, 1988.
29. O'Callaghan, J.P., Niedzwiecki, D.M. and Means, J.C.: Variations in the neurotoxic potency of trimethyltin. *Brain Res. Bull.* 22: 637-642, 1989.

30. O'Callaghan, J.P., Brinton, R.E. and McEwen, B.S.: Glucocorticoids regulate the concentration of glial fibrillary acidic protein throughout the brain. *Brain Res.* 494: 159-161, 1989.
31. Wainfan, E., Dizik, M. and O'Callaghan, J.P.: Prolonged survival of female AKR mice fed diets supplemented with methionine and choline. *Carcinogenesis* 11: 361-363, 1990.
32. O'Callaghan, J.P., Miller, D.B. and Reinhard, J.F., Jr.: Characterization of the origins of astrocyte response to injury using the dopaminergic neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine. *Brain Res.* 521: 73-80, 1990.
33. O'Callaghan, J.P., Miller, D.B. and Reinhard, J.F., Jr.: MPTP-induced damage of striatal dopaminergic fibers attenuates subsequent astrocyte response to MPTP. *Neurosci. Lett.* 117: 228-233, 1990.
34. Burdette, L.J. and O'Callaghan, J.P.: Ca^{2+} /calmodulin-dependent protein phosphorylation is not altered by amygdaloid kindling. *Brain Res. Bull.* 26: 455-459, 1991.
35. O'Callaghan, J.P. and Miller, D.B.: The concentration of glial fibrillary acidic protein increases with age in the mouse and rat brain. *Neurobiol. Aging* 12: 171-174, 1991.
36. Gordon, C.J., Watkinson, W.P., O'Callaghan, J.P. and Miller, D.B.: Effects of 3,4-methylenedioxymethamphetamine on autonomic thermo-regulatory responses of the rat. *Pharmacol. Biochem. Behav.* 38: 339-344, 1991.
37. Frankfurt, M., O'Callaghan, J. and Beaudet, A.: 5,7-Dihydroxytryptamine injections increase glial fibrillary acidic protein in the hypothalamus of adult rats. *Brain Res.* 549: 138-140, 1991.
38. Miller, D.B., Reinhard, J.F., Jr., Daniels, A.J. and O'Callaghan, J.P.: Diethyldithiocarbamate potentiates the neurotoxicity of in vivo 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and of in vitro 1-methyl-4-phenylpyridinium (MPP⁺). *J. Neurochem.* 57: 541-549, 1991.
39. O'Callaghan, J.P., Brinton, R.E. and McEwen, B.S.: Glucocorticoids regulate the synthesis of glial fibrillary acidic protein in intact and adrenalectomized rats but do not affect its expression following brain injury. *J. Neurochem.* 57: 860-869, 1991.
40. O'Callaghan, J.P.: Quantification of glial fibrillary acidic protein: Comparison of slot-immunobinding assays with a novel sandwich ELISA. *Neurotoxicol. Teratol.* 13: 275-281, 1991.
41. Reinhard, J.F., Jr. and O'Callaghan, J.P.: Measurement of tyrosine hydroxylase apoenzyme protein by enzyme-linked immunosorbent assay (ELISA): Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal tyrosine hydroxylase activity and content. *Anal. Biochem.* 196: 296-301, 1991.
42. Haykal-Coates, N., O'Callaghan, J.P., Reinhard, J.F., Jr. and Jensen, K.F.: Pargyline and gamma butyrolactone enhance tyrosine hydroxylase immunostaining of nigrostriatal axons. *Brain Res.* 556: 353-357, 1991.
43. O'Callaghan, J.P.: Assessment of neurotoxicity: Use of glial fibrillary acidic protein as a biomarker. *Biomed. Environ. Sci.* 4: 197-206, 1991.
44. Miller, D.B., Luebke, R.W., Reinhard, J.F., Jr. and O'Callaghan, J.P.: The neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) alters immune function when given in combination with diethyldithiocarbamate (DDC). *Ann. NY Acad. Sci.* 648: 309-311, 1992.

45. Sparber, S.B., O'Callaghan, J.P. and Berra, B.: Ganglioside treatment partially counteracts neurotoxic effects of trimethyltin but may itself cause neurotoxicity in rats: Experimental results and a critical review. *Neurotoxicology* 13: 679-700, 1992.
46. Genter, M.B., Llorens, J., O'Callaghan, J.P., Peele, D.B., Morgan, K.T. and Crofton, K.M.: Olfactory toxicity of β,β' -iminodipropionitrile (IDPN) in the rat. *J. Pharmacol. Exp. Ther.* 263: 1432-1439, 1992.
47. O'Callaghan, J.P. and Seidler, F.J.: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced astrogliosis does not require activation of ornithine decarboxylase. *Neurosci. Lett.* 148: 105-108, 1992.
48. Goodlett, C.R., Leo, J.T., O'Callaghan, J.P., Mahoney, J.C. and West, J.R.: Transient cortical astrogliosis induced by alcohol exposure during the neonatal brain growth spurt in rats. *Dev. Brain Res.* 72: 85-97, 1993.
49. Llorens, J., Crofton, K.M. and O'Callaghan, J.P.: Administration of 3,3'-iminodipropionitrile to the rat results in region-dependent damage to the CNS at levels above the brain stem. *J. Pharmacol. Exp. Ther.* 265: 1492-1498, 1993.
50. Day, J.R., Laping, N.J., Brown, S.A., Lampert-Etchells, M., Brown, S.A., O'Callaghan, J.P., McNeill, T.H. and Finch, C.E.: Gonadal steroids regulate the expression of GFAP in the adult male rat hippocampus. *Neuroscience* 55: 435-443, 1993.
51. Miller, D.B. and O'Callaghan, J.P.: The interactions of MK-801 with the amphetamine analogues- d-methamphetamine, d-3,4-methylene-dioxymethamphetamine or d-fenfluramine: neural damage and neural protection. *Ann. N.Y. Acad. Sci.* 679: 321-324, 1993.
52. O'Callaghan, J.P.: A potential role for altered protein phosphorylation in the mediation of developmental neurotoxicity. *Neurotoxicology* 15: 29-40, 1994.
53. Deamer, N.J., O'Callaghan, J.P. and Genter, M.B.: Olfactory toxicity resulting from dermal application of 2,6-dichlorobenzo-nitrile (dichlobenil) in the C57Bl mouse. *Neurotoxicology* 15: 287-293, 1994.
54. Goldey, E.S., O'Callaghan, J.P. Stanton, M.E., Barone, S. and Crofton, K.M.: Developmental neurotoxicity: Evaluation of testing procedures with methylazoxymethanol and methylmercury. *Fund. Appl. Toxicol.* 23: 447-464, 1994.
55. McMillian, M.K., Thai, L., Hong, J.-S., O'Callaghan, J.P., and Pennypacker, K.R.: Brain injury in a dish: a model for reactive gliosis. *Trends in Neuroscience* 17: 138-142, 1994.
56. O'Callaghan, J.P. and Miller, D.B.: Neurotoxicity profiles of substituted amphetamines in the C57/Bl6J mouse. *J. Pharmacol. Exp. Ther.* 270: 741-751, 1994.
57. Miller, D.B. and O'Callaghan, J.P.: Environment-, drug- and stress- induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57/Bl6J mouse. *J. Pharmacol. Exp. Ther.* 270: 752-760, 1994.
58. Laping, N.J., Teter, B., Anderson, C.P., Osterburg, H.H., O'Callaghan, J.P., Johnson, S.A. and Finch, C.E.: Age-related increases in glial fibrillary acidic protein do not show proportionate changes in transcription rates or DNA methylation in cerebral cortex and hippocampus of male rats. *J. Neurosci. Res.* 39:710-717, 1994.
59. Rozovsky, I., Laping, N.J., Krohn, K., Teter, B., O'Callaghan, J.P. and Finch, C.E.: Transcriptional regulation of glial fibrillary acidic protein by corticosterone in rat astrocytes *in vitro* is influenced by the duration of time in culture and by astrocyte-neuron interactions. *Endocrinol.* 136: 2066-2073, 1995.

60. Martin, P.M. and O'Callaghan, J.P.: A direct comparison of GFAP immunocytochemistry and GFAP concentration in various regions of ethanol-fixed rat and mouse brain. *J. Neurosci. Methods* 58: 181-192, 1995.
61. Fix, A.S., Wrightman, K.A. and O'Callaghan, J.P.: Reactive gliosis induced by MK-801 in the rat posterior cingulate/retrosplenial cortex: GFAP evaluation by sandwich ELISA and Immunocytochemistry. *Neurotoxicology* 16: 229-238, 1995.
62. Gordon, C.J. and O'Callaghan, J.P.: Trimethyltin-induced neuropathy in the rat: interaction with thermoregulation. *Neurotoxicology* 16: 319-326, 1995.
63. Johnson, K.B., Moy, S.S. Knapp, D.J., Criswell, H.E., O'Callaghan, J.P., Mueller, R.A., Breese, G.R.: NMDA antagonists MK-801 and CGS-19755 dissociate behavioral and striatal c-fos sensitization to a D₁-dopamine agonist in neonatal 6-hydroxydopamine-lesioned rats. *J. Pharmacol. Exp. Ther.* (submitted).
64. Guilarte, T.R., Kuhlmann, A.C., O'Callaghan, J.P. and Miceli, R.C.: Enhanced expression of peripheral benzodiazepine receptors in trimethyltin-exposed rat brain: A biomarker of neurotoxicity. *Neurotoxicology* 16: 441-450, 1995.
65. McCann, M.J., O'Callaghan, J.P., Martin, P.M., Bertram, T. and Streit, W.J.: Differential activation of microglia and astrocytes following trimethyl-tin-induced neurodegeneration. *Neuroscience* 72: 273-281, 1996.
66. Appel, N.M., Rappoport, S.I. and O'Callaghan, J.P.: Sequelae of parenteral domoic acid administration in rats: comparison of effects on different anatomical markers in brain. *Synapse* 25: 350-358, 1997.
67. Appel, N.M., Rappoport, S.I., O'Callaghan, J.P., Bell, J.M. and Freed, L.M.: Sequelae of parenteral domoic acid administration in rats: comparison of effects on different metabolic markers in brain. *Brain Res.* 754: 55-64, 1997.
68. O'Callaghan, J.P. and Miller, D.B. RE: Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. *JAMA* 278: 2141, 1997.
69. Yokel, R.A. and O'Callaghan, J.P.: An aluminum-induced increase in GFAP is attenuated by some chelators. *Neurotoxicology and Teratology* 20: 55-60, 1998.
70. Day, J.R., Frank, A.T., O'Callaghan, J.P. Jones, B.C. and Anderson, J.E: The effect of age and testosterone on the expression of GFAP in the rat cerebellum. *Exp. Neurol.* 151: 343-346, 1998.
71. Buxbaum, J.D., Thinakaran, G., Koliatsos, V., O'Callaghan, J.P., Slunt, H.H., Price, D.L. and Sisodia, S.S.: Alzheimer amyloid protein precursor in the rat hippocampus: Transport and processing through the perforant path. *J. Neurosci.* 18: 9629-9637, 1998.
72. Dugar, A., Patanow, C., O'Callaghan, J.P. and Lakoski, J.M.: Immunohistochemical localization and quantification of GFAP and SNAP-25 in the aging hippocampus following administration of 5,7-dihydroxytryptamine. *Neuroscience* 85: 123-133, 1998.
73. Miller, D.B., Ali, S.F., O'Callaghan, J.P., and Laws, S.C.: The impact of gender and estrogen on striatal dopaminergic neurotoxicity. *Ann. NY Acad. Sci.* 844: 153-165, 1998.
74. O'Callaghan, J.P., Martin, P.M. and Mass, M.J.: The MAP kinase cascade is activated prior to the induction of gliosis in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of dopaminergic neurotoxicity. *Ann. NY Acad. Sci.* 844: 40-49, 1998.
75. O'Callaghan, J.P.: Astrocytes: Key players in mediation or modulation of neurotoxic responses? *Neurotoxicol.* 19: 35-36, 1998.

76. Fienberg, A.A., Hiroi, N., Mermelstein, P.G., Song, W.-J., Snyder, G.L. Nishi, A., Cheramy, A., O'Callaghan, J.P., Miller, D.B., Cole, D.G., Corbett, R., Haile, C.N., Cooper, D.C., Onn, S.P., Grace, A.A., Ouimet, C.C., White, F.J., Hyman, S.E., Surmeier, D.J., Girault, J.-A., Nestler, E.J. and Greengard, P.: DARPP-32, regulator of the efficacy of dopaminergic neurotransmission. *Science (Wash., D.C.)* 281:838-842, 1998.
77. Day, J.R., Frank, A.T., O'Callaghan, J.P. and DeHart, B.W.: The effects of microgravity and bone morphogenetic protein II on GFAP in rat brain. *J. Appl. Physiol.* 85: 716-722, 1998.
78. Schmidt, G.R., Hossner, K.L., Yemm, R.S., Gould, B.H. and O'Callaghan, J.P.: An enzyme-linked immunosorbant assay (ELISA) for glial fibrillary acidic protein (GFAP) as an indicator of the presence of brain or spinal cord in meat. *J. Food Protect.* 62: 394-397, 1999.
79. O'Callaghan, J.P., Imai, H., Miller, D.B. and Minter, A.: Quantitative immunoblots of proteins resolved from tissue homogenates: underestimation of specific protein concentration and of treatment effects. *Anal. Biochem.* 274: 18-26, 1999.
80. Mani, S.K., Fienberg, A.A., O'Callaghan, J.P., Snyder, G.L., Allen, P.B., Mitchell, A.J., Bibb, J., Greengard, P. and O'Malley, B.W.: The neuronal phosphoprotein DARPP-32 is required for dopamine and progesterone-facilitated sexual behavior in female rodents. *Science (Wash., D.C.)* 287: 1053-1056, 2000.
81. Kalia, M., O'Callaghan, J.P. and Miller, D.B.: Comparative study of fluoxetine, sibutramine, sertraline and dexfenfluramine on the morphology of serotonergic nerve terminals using serotonin immunohistochemistry. *Brain Res.* 858: 92-105, 2000.
82. Pennypacker, K.R., Yang, X., Gordon, M.N., Benkovic, S., Miller, D. and O'Callaghan, J.P.: Long-term induction of FRA-2 after methamphetamine-, methylenedioxymethamphetamine-, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- and trimethyltin-induced brain injury. *Neuroscience* 101:913-919, 2000.
83. Lam, H.R., Ladefoged, O., Østergard, G., and O'Callaghan, J.P.: Inhalation exposure to white spirit causes region-dependent alterations in the levels of glial fibrillary acidic protein. *Neurotox. Teratol.* 22:725-731, 2000.
84. Pennypacker, K.R., Eidizedeh, S., Kassed, C.A., O'Callaghan, J.P., Sanberg, R., and Willing, A.E.: Expression of FRA-2 in rat hippocampus after middle cerebral arterial occlusion. *Neurosci. Lett.* 289:1-4, 2000.
85. Pennypacker, K.R., Kassed, C.A., Eidizadeh, S. and O'Callaghan, J.P.: Prolonged induction of transcription factors in brain injury. *Acta Neurobiologiae Experimentalis* 60: 515-530, 2000.
86. Bibb, J.A., Nishi, A., O'Callaghan, J.P., Snyder, G. Horiuchi, A., Lan, M., Ule, J., Pelech, S.L., Meijer, L., Saito, T., Hisanaga, S., Czernik, A.J., Nairn, A.C. and Greengard, P.: Phosphorylation of protein phosphatase inhibitor-1 by CDK5. *J. Biol. Chem.* 276:14490-14497, 2001.
87. Ross, G.W., Sharp, D.S., O'Callaghan, J.P., Petrovitch, H., Miller, D.B., Nelson, J., Launer, L.J. and White, L.R.: Glial fibrillary acidic protein levels at death in the neocortex of elderly Japanese-American men with Alzheimer's disease. *Acta Neurol. Scand.* 107:318-323, 2003.
88. Johnson, E.A., O'Callaghan, J.P. and Miller, D.B.: Chronic treatment with supraphysiological levels of corticosterone enhances d-MDMA-induced dopaminergic neurotoxicity in the C57Bl/6J female mouse. *Brain Res.* 933: 130-138, 2002.

89. Johnson, E.A., Shvedova, A.A., Kisin, E., O'Callaghan, J.P., Kommineni, C., Miller, D.B.: d-MDMA during vitamin E deficiency: effects on dopaminergic neurotoxicity and hepatotoxicity. *Brain Res.* 933: 150-163, 2002.
90. Little, A.R. and O'Callaghan, J.P.: Astrogliosis in the adult and developing CNS: Is there a role for cytokines? *Neurotoxicology* 22: 607-618, 2001.
91. Bowyer, J.F., Holson, R.R., Miller, D.B. and O'Callaghan, J.P.: Phenobarbital and dizocilpine can block methamphetamine-induced neurotoxicity in mice by mechanisms that are independent of thermoregulation. *Brain Res.* 919: 179-183, 2001.
92. Schmidt, G.R., Yemm, R.S., Childs, K.D., O'Callaghan, J.P. and Hossner, K.L.: The presence of central nervous system tissue on beef carcasses and in comminuted beef. *J. Food Protection* 64: 2047-2052, 2001.
93. Sriram, K., Benkovic, S.A., Miller, D.B. and O'Callaghan, J.P.: Leptin-deficient (ob/ob) condition exacerbates toxicant-induced neurodegeneration. *Neuroscience* 115: 1335-1346, 2002.
94. Gordon, M.N., Holcomb, L.A., Jantzen, P., DiCarlo, G., Wilcock, D., Boyett, K.W., Connor, K., Melanchrino, J., O'Callaghan, J.P. and Morgan, D.: Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. *Exp. Neurol.* 173: 183-195, 2002.
95. Little, A.R., Benkovic, S.A., Miller, D.B. and O'Callaghan, J.P.: Chemically-induced neuronal damage and gliosis: Enhanced expression of the proinflammatory cytokine, MCP-1, without a corresponding increase in proinflammatory cytokines. *Neuroscience* 115: 307-320, 2002.
96. Sriram, K., Matheson, J.M., Benkovic, S.A., Miller, D.B., Luster, M.I. and O'Callaghan, J.P.: Mice deficient in the TNF- α receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. *FASEB J.* 16: 1474-1476, 2002
97. Rozovsky, I., Hoving, S., Anderson, C.P., O'Callaghan, J. and Finch, C.E.: Equine estrogens induce apolipoprotein E and GFAP in mice glial cultures. *Neurosci. Lett.* 323: 191-194, 2002.
98. Miller, D.B. and O'Callaghan, J.P.: Elevated environmental temperature and methamphetamine neurotoxicity. *Environmental Research* 92: 48-53, 2003.
99. MacPhail, R.C., O'Callaghan, J.P. and Cohn, J.: Acquisition, steady-state performance and the effects of trimethyltin on the operant behavior and hippocampal GFAP of Long-Evans and Fischer-344 rats. *Neurotoxicol. Teratol.* 25: 481-490, 2003.
100. Luellen, B.A., Miller, D.B., Chisnell, A.C., Murphy, D.L., O'Callaghan, J.P. and Andrews, A.M.: Neuronal and Astroglial Responses to the Serotonin and Norepinephrine Neurotoxin: 2'-NH₂-MPTP. *J. Pharmacol. Exp. Ther.* 307: 923-931, 2003.
101. Bowyer, J.F., Harris, A.J., Delongchamp, R.R., Jakab, R., Miller, D.B., Little, A.R. and O'Callaghan, J.P.: Selective changes in gene expression in cortical regions sensitive to amphetamine during the neurodegenerative process. *Neurotoxicology* 25: 555-572, 2004.
102. Johnson, E.A., O'Callaghan, J.P. and Miller, D.B.: Brain concentrations of d-MDMA are increased after stress. *Psychopharmacology* 173: 278-286, 2004.
103. Benkovic, S.A., O'Callaghan, J.P. and Miller, D.B.: Sensitive indicators of injury reveal hippocampal damage in C57BL/6J mice treated with kainic acid in the absence of tonic-clonic seizures. *Brain Res.* 1024: 59-76, 2004.
104. Sriram, K., Benkovic, S.A., Hebert, M.A., Miller, D.B. and O'Callaghan, J.P.:

- Activation of the gp130-JAK/STAT3 pathway in astrocytes precedes the induction of GFAP in the MPTP model of dopaminergic neurodegeneration: Key signaling pathway for astrogliosis? *J. Biol. Chem.* 279: 19936-19947, 2004.
105. O'Callaghan, J.P. and Sriram, K.: Focused microwave irradiation of the brain preserves *in vivo* protein phosphorylation: Comparison with other methods of sacrifice and analysis of multiple phosphoproteins. *J. Neurosci. Methods* 135: 159-168, 2004
 106. De Groot, D., Pelgrim, M., Pakkenberg, B., Kaufmann, W., Bos-Kuijpers, M., O'Callaghan, J., Lammers, J., Waalkens-Berendsen, I., Waanders, M.M. and Gundersen, H.-J.: Regulatory developmental neurotoxicity testing: a model study focusing on conventional neuropathology endpoints and other perspectives. *Environmental Toxicol. and Pharmacol.* 19: 745-755, 2005.
 107. Kashon, M.L., Ross, G.W., O'Callaghan, J.P., Miller, D.B., Petrovich, H., Burchfiel, C.M., Sharp, D.S. and White, L.R.: Associations of cortical astrogliosis with cognitive performance and dementia status. *J. Alzheimer's Disease* 6: 595-604, 2004.
 108. Reed, M.D., Blair, L.F., Burling, K., Daly, I., Gigliotti, A.P., Gudi, R., Mercieca, M.D. McDonald, J.D., Naas D.J., O'Callaghan, J.P., Seilkip, S.K., Ronsko, N.L., Wagner, V.O. and Kraska, R.C.: Health effects of subchronic exposure to diesel-water emulsion emission. *Inhal. Toxicol.* 17: 851-870, 2005.
 109. Toscano, C.D., O'Callaghan, J.P. and Guilarte, T.R.: Extracellular regulated kinase $\frac{1}{2}$ and calcium/calmodulin dependent protein kinase II are differentially regulated in the hippocampus of Pb²⁺-exposed rats. *Brain Res.* 1044: 51-58, 2005.
 110. Sriram, K., Matheson, J.M., Benkovic, S.A., Miller, D.B., Luster, M.I. and O'Callaghan, J.P. : Microglial activation and MPTP-induced neurotoxicity: Region-specific role for TNF- α . *FASEB J.* 20: 670-682, 2006.
 111. O'Callaghan, J.P. and Sriram, K.: GFAP and Other Glial Proteins as Biomarkers of Neurotoxicity. *Expert Opinion in Drug Safety* 4: 433-442, 2005.
 112. Groot, D.M.G., Hartgring, S., van de Horst, L., Moerkens, M., Otto, M., Bos-Kuijpers, M.H.M., Kaufmann, W.S.H., Lammers, J.H.C.M., O'Callaghan, J.P., Waalkens-Berendsen, I.D.H., Pakkenberg, B., Gundersen, H.J.G.: Two- and 3-D assessment of neuropathology in rat brain after prenatal exposure to methylazoxymethanol, a model for developmental neurotoxicity. *Rep. Toxicol.* 20: 417-432, 2005.
 113. Parkin, M.C., O'Callaghan, J.P., Bole, D.G., Ueda, T. and Kennedy, R.T.: Sample dependent effects on the neuropeptidome in rat brain tissue preparations detected by capillary LC-MS. *Analyt. Chem.* 77: 6331-6338, 2005.
 114. Wei, H., Dean, S.L., Parkin, M.C., Nolkrantz, K., O'Callaghan, J.P. and Kennedy, R.T.: Microscale sample deposition onto hydrophobic target plates for trace level detection of neuropeptides in brain tissue by MALDI-MS. *J. Mass Spectroscopy* 40: 1338-1346, 2005.
 115. Benkovic, S.A., O'Callaghan, J.P. and Miller, D.B.: Regional neuropathology following kainic acid intoxication in adult and aged C57Bl/6J mice. *Brain Res.* 1070: 215-231, 2006.
 116. Sriram, K., Miller, D.B. and O'Callaghan, J.P.: Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: Role of TNF- α . *J. Neurochem.* 96: 706-719, 2006.
 117. Bowyer, J.F., Pogge, AR., Delonchamp, R.R., O'Callaghan, J.P., Patel, K.M., Vrana, K.E. and Freeman, W.M.: A threshold neurotoxic exposure to amphetamine inhibits the

- expression of genes in the parietal cortex that are involved in synaptic plasticity. *Neuroscience* 100: 428-436, 2007.
118. Little, A.R. and O'Callaghan, J.P.: CCL2 and its receptors are negatively regulated by corticosterone in the rat brain. *Neurosci. Lett.* 399: 162-166, 2006.
 119. Schulte, P., Ostry, A., Blanciforti, L.A., Cutlip, R., Krajnak, K., Luster, M., Munson, A., O'Callaghan, J., Parks, C., Simeonova, P., Wagner, G. and Miller, D.: Work, Obesity, and Occupational Safety and Health. *Am J. Public Health* 97: 428-436, 2007.
 120. Antonini, J.M., O'Callaghan, J.P. and Miller, D.B.: Development of an animal model to study the potential neurotoxic effects associated with welding fume inhalation. *Neurotoxicology* 27: 745-751, 2006.
 121. Miller, D.B. and O'Callaghan, J.P.: The pharmacology of wakefulness. *Metabolism* 55: S13-S19, 2006.
 122. Damiani, C.L. and O'Callaghan, J.P.: Recapitulation of cell signaling events associated with astrogliosis using the brain slice preparation. *J. Neurochem.* 100: 720-726, 2007.
 123. Zinnanti, W.J., Lazovic, J., Housman, C., Towfighi, J., LaNoue, K., O'Callaghan, J.P., Woontner, M., Goodman, S.I., Connor, J.R. and Cheng, K.C.: Mechanism of age-dependent susceptibility and novel treatment strategy in glutaric acidemia type I. *J. Clin Investigation.* 117: 3258-3270, 2007.
 124. Hubbs, A.F., Benkovic, S.A., Miller, D.B., Battelli, L.A., Schwegler-Berry, D. and Ma, Q. Vacuolar Leukoencephalopathy with Widespread Astrogliosis in Mice Lacking Transcription Factor Nrf2. *Am. J. Pathol.* 170: 2068-2076, 2007.
 125. Benkovic, S.A., O'Callaghan, J.P. and Miller, D.B.: Exercise provides neuroprotection without altering seizure susceptibility following kainic acid intoxication in C57Bl6/J mice. *J. Neurosci.* (submitted).
 126. Wei, H., Nolkranz, K., Parkin, M.C., Chisolm, C.N., O'Callaghan, J.P. and Kennedy, R.T.: Identification and quantification of neuropeptides in brain tissue by capillary liquid chromatography coupled off-line to MALDI-TOF and MALDI-TOF/TOF-MS. *Anal. Chem.* 78: 4342-4351, 2006.
 127. Reed, M.D., Blair, L.F., Burling, K., Daly, I., Gigliotti, A.P., Gudi, R., Mercieca, M.D., McDonald, J.D., O'Callaghan, J.P., Seilkop, S.K., Ronskoh, N.L., Wagner, V.O., Kraska, R.C.: Health effects of subchronic exposure to diesel-water-methanol emulsion emission. *Toxicol. Ind. Health* 22: 65-85, 2006.
 128. Sriram, K. and O'Callaghan, J.P.: Divergent roles for tumor necrosis factor- α in the brain. *J. Neuroimmun. Pharm.* 2: 140-153, 2007.
 129. El-Fawal, H.A.N. and O'Callaghan, J.P.: Autoantibodies to neurotypic and gliotypic proteins as biomarkers of neurotoxicity: assessment of trimethyltin (TMT). *Neurotoxicology* 29: 109-115, 2008.
 130. Scharf, M.T., Mackiewicz, Miroslaw, Naidoo, N., O'Callaghan, J.P. and Pack, A.I.: AMP-activated protein kinase phosphorylation in brain is dependent on method of sacrifice and tissue preparation. *J. Neurochem.* 105: 833-841, 2008.
 131. Fox, D.A., Subbarao, V.K., Hamilton, W.R., Johnson, J.E. and O'Callaghan, J.P.: Low-level human equivalent gestational lead exposure produces supernormal scotopic electroretinograms, increased retinal neurogenesis and decreased retinal dopamine utilization in rats. *Environ. Health Perspect.* 116: 618-625, 2008.
 132. Nishi A, Kuroiwa M, Miller D, O'Callaghan JP, Bateup HS, Shuto T, Sotogaku N, Fukuda T, Heintz N, Greengard P, Snyder GL. Distinct roles of PDE4 and PDE10A in the

- regulation of cAMP/PKA signaling in the striatum. *J Neurosci.* 28: 10460-10471, 2008.
133. Meyer DA, Richer E, Benkovic S, Kansy JW, Hale C, Moy L, Kim Y, O'Callaghan JP, Tsai L, Greengard P, Nairn AC, Cowan CW, Miller D, Antich P, Bibb JA. Striatal dysregulation of Cdk5 alters locomotor responses to cocaine, motor learning, and dendritic morphology. *PNAS* 105: 18561-18566, 2008.
 134. Wharton, S.B., O'Callaghan, J.P., Savva, G.M., Nicoll, J.A.R., Matthews, F., Simpson, J.E., Forster, G., Shaw, P.J., Brayne, C. and Ince P.G.: Population variation in GFAP levels in brain aging: Relationship to Alzheimer-type pathology and dementia. *Dementia and Geriatric Disorders* 27: 465-473, 2009.
 135. Magiatis, P., Polychronopoulos, P., Skaltsounis, A-L., Lozach, O., Meijer, L., Miller D.B., and O'Callaghan, J.P.: Indirubins affect striatal monoamines and block striatal damage in MPTP and kainite models of neurotoxicity. *Neurotoxicology and Teratology* 32: 212-219, 2010.
 136. Benkovic, S.A., O'Callaghan, J.P. and Miller, D.B.: Protracted exposure to supraphysiological levels of corticosterone does not cause neuronal loss or damage and protects against kainic acid-induced neurotoxicity in the hippocampus of C57Bl/6J mice. *Neurotoxicology* 30: 965-976, 2009.
 137. Antonini, J.M., Sriram, K., Benkovic, S.A., Roberts, J.R., Stone, S., Chen, B.T., Schwegler-Berry, J, Jefferson, A.M., Billig, B.K., Felton, C.M., Ma, F., Hammer, M. Frazer, D.G., James P. O'Callaghan, Diane B. Miller: Mild Steel Welding Fume Causes Manganese accumulation and subtle neuroinflammatory changes but not overt neuronal damage in discrete brain regions of rats after short-term inhalation exposure. *Neurotoxicology* 30: 915-925, 2009.
 138. Zhu, H., O'Brien, J., O'Callaghan, J.P., Miller, D.B., Zhang, Q., Rana, M., Tsui, T., Hendrick, J.P., Wennogle, L.P. and Snyder, G.L: Exposure to the nerve agent diisopropyl-phosphorofluoridate (DFP) in vivo elicits site-specific and regionally-restricted changes in protein phosphorylation in mouse brain. *Brain Res.* 1342: 11-23, 2010.
 139. DiNapoli, V.A., Benkovic, S., Li, X., Kelly, K.A., Miller, D.B., Rosen, C.L., Huber, J.D. and O'Callaghan, J.P.: Age exaggerates proinflammatory cytokine signaling and truncates STAT3 signaling following ischemic stroke in the rat. *Neuroscience* 170: 633-644, 2010.
 140. Peng, Y, Zhang, Q., Snyder, G., Zhu, H., Yao, W., Tomesch, J., Papke, R.L., O'Callaghan, J.P., Welsh, W.J. and Wennogle, L.: Discovery of Novel Alpha7 Nicotinic Receptor Antagonists. *Bioorg. Med. Chem. Lett.* 20:4825-30, 2010.
 141. O'Callaghan, J.P. and Miller, D.B.: Spinal glia and chronic pain. *Metabolism* 59, Supp. 1: S21-S26, 2010
 142. Little, A.R., Miller, D.B., Li, S., Kashon, M.L. and O'Callaghan, J.P.: Trimethyltin-induced neurotoxicity: gene expression pathway analysis, q-rt-PCR and immunoblotting reveal early effects associated with hippocampal damage and gliosis. *Neurotoxicol. Teratol.* 34: 72-82, 2012.
 143. Wichitnithad, W., O'Callaghan, J.P., Miller, D.B., Train, B.C. and Callery, P.S.: Time-dependent slowly reversible inhibition of monamine oxidase A by N-substituted 1,2,3,6-tetrahydropyridines. *Bioorg. Med. Chem.* 19: 482-4892, 2011.

144. Xiao, L., O'Callaghan, J.P. and O'Donnell, J.M.: Effects of repeated treatment with phosphodiesterase-4 inhibitors on cyclic AMP signaling, hippocampal neurogenesis, and behavior in the forced-swim test. *J. Pharmacol. Exp. Ther.* 338: 641-647, 2011.
145. Fox, D.A., Hamilton, W.R., Johnson, J.E., Xiao, W., Chaney, S., Mukherjee, S., Miller, D.B. and O'Callaghan, J.P.: Gestational lead exposure selectively decreases retinal dopamine amacrine cells and dopamine content in adult mice. *Toxicol. Appl. Pharmacol.* 256: 258-267, 2011.
146. Torres-Altora, M.I., Mathur, B.N., Drerup, J.M., Thomas, R., Lovinger, D., O'Callaghan, J.P. and Bibb, J.A.: Organophosphates dysregulate dopamine signaling, glutamatergic neurotransmission, and induce neuronal injury markers in striatum. *J. Neurochem.* 119: 303-313, 2011.
147. Mochel, F., Durant, B., Meng, X., O'Callaghan, J., Yu, H., Brouillet, E., Wheeler, V.C., Humbert, S., Schiffmann, R. and Durr, A.: Early alterations of brain cellular energy homeostasis in Huntington disease models. *J. Biol. Chem.* 287: 1361-1370, 2012.
148. Ross, G.W., Duda, J.E., Abbott, R.D., Pellizzari, E., Petrovitch, H., Miller, D.B., O'Callaghan, J.P., Tanner, C.M., Noorigian, J.V., Masaki, K., Launer, L. and White, L.R.: Relationship of Brain Organochlorine Levels with Lewy Pathology: the Honolulu-Asia Aging Study. *Movement Disorders* 27: 1418-1424, 2012.
149. Kelly, K.A., Bowyer, J.F., Miller, D.B. and O'Callaghan, J.P.: Chronic exposure to corticosterone enhances the neuroinflammatory and neurotoxic responses to methamphetamine. *J. Neurochem.* 122: 995-1009, 2012.
150. Miller, D.B. and O'Callaghan, J.P. Personalized medicine in the diagnosis and treatment of major depressive disorder-opportunities and pitfalls. *Metabolism* 62: S34-S39, 2013.
151. Jones, B.C., Miller, D.B., O'Callaghan, J.P., L. Lu., Unger, E.L., Alam, G., Williams, R.W.: Systems analysis of genetic variation in MPTP neurotoxicity in mice. *Neurotoxicology* 37: 26-34, 2013.
152. O'Callaghan, J.P., Kelly, K.A., Van Gilder, R.L., Sofroniew, M.V. and Miller, D.B.: Early activation of STAT3 regulates reactive astrogliosis induced by diverse forms of neurotoxicity *PLoS ONE* 9(7): e102003. doi:10.1371/journal.pone.0102003, 2014.
153. Robson, M., Turner, R., O'Callaghan, J.P. and Matsumoto, R.: SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation. *Experimental Neurology* 254: 180-89, 2014.
154. Snyder, G.L., Vanover, K.E., Zhu, H., Miller, D.B., O'Callaghan, J.P., Tomesch, J., Peng, L., Zhang, Q., Krishnan, V., Hendrick, J.P., Nestler, E.J., Davis, R., Wenogle, L.P., and Mates, S.: Unique functional profile of ITI-007, a modulator of serotonin, dopamine and glutamate neurotransmission. *Psychopharmacology* (in press).
155. Matsumoto, R.R., Seminerio, M.J., Turner, R.C., Robson, M.J., Miller, D.B. and O'Callaghan, J.P.: Methamphetamine-induced toxicity: an updated review on issues relate to hyperthermia. *Pharmacol. Ther.* (in press).
156. O'Callaghan, J.P., Daughtrey, W.C., Clark, C.R., Schreiner, C.A. and White, R.: Health Assessment of Gasoline and Fuel Oxygenate Vapors: Neurotoxicity Evaluation. *Regulatory Toxicol. Pharmacol.* 70: S35-S42, 2014.
157. Gray, T.M., Steup, D., Roberts, L.G., O'Callaghan, J.P., Hoffman, G., Schreiner, C. and Clark, C.R.: Health Assessment of Gasoline and Fuel Oxygenate Vapors: Reproductive

- Toxicity Assessment. *Regulatory Toxicol Pharmacol.* (in press).
158. Jones, B.C., O'Callaghan, J.P., Lu, L., Williams, R.W., Alama, G., Miller, D.B. Genetic Correlational Analysis Reveals no Association between MPP+ and the Severity of Striatal Dopaminergic Damage Following MPTP Treatment in BXD mouse strains. *Neurotoxicol. Teratol.* 45: 91-92, 2014.
 159. Panos, J.J., O'Callaghan, J.P., Miller, D.B. and Ferguson, S.A.: Effects of developmental methylphenidate (MPH) treatment on monoamine neurochemistry of male and female rats. *Neurotoxicology* 45: 70-74, 2014.
 160. Miller, D.B. and O'Callaghan, J.P.: Biomarkers of Parkinson's disease (PD): where we are and where we are going. *Metabolism* 64: S40-6, 2015.
 161. Elliott, A.S., Huber, J.D., O'Callaghan, J.P., Rosen, C.L. and Miller, D.B.: A review of sleep deprivation studies evaluating the brain transcriptome. *SpringerPlus* 3: 728, 2014.
 161. O'Callaghan, J.P., Kelly, K.A., Locker, A.R., Miller, D.B. and Lasley, S.M.: Corticosterone Primes the Neuroinflammatory Response to DFP in Mice: Potential Animal Model of Gulf War Illness *J. Neurochem.* 2015 Mar 5. doi: 10.1111/jnc.13088.
 162. Roberts R., Aschner M., Calligaro D., Guilarte T.R., Hanig J.P., T Herr D., Hudzik, T.J., Jeromin, A., Kallman M.J., Liachenko S., Lynch J.J. III, Miller D.B., Moser V.C., O'Callaghan J., Slikker W. Jr., Paule, M.G. Translational Biomarkers of Neurotoxicity: the Way Forward? *Tox Sci.* (in house review)
 163. White, R.F., Steele, L., O'Callaghan, J.P., Sullivan, K., Barlow, C., Binns, J.H., Bloom, F.E., Bunker, J.A., Crawford, F., Golomb, B.A., Graves, J.C., Hardie, A., Klimas, N, Knox, M, Meggs, W., Melling, J., Ondra, S.L., Philbert, M.A., Grashow, R.: Gulf War illness and other health problems in veterans of the 1990-1991 Gulf War: Effects of exposures to neurotoxicants. *Cortex* (submitted).

Book Chapters, Conference Proceedings and Commentaries:

1. Clouet, D.H., O'Callaghan, J.P. and Williams, N.: The effects of opiates on calcium-stimulated phosphorylation of synaptic membrane proteins in intact synaptosomes from rat striatum. In: *Characteristics and Function of Opioids*, eds: Van Ree and Terenius, Elsevier/North Holland Biomedical Press, 1978, pp 351-352.
2. Clouet, D.H., O'Callaghan, J.P., and Williams, N: The effects of opiates on endogenous phosphorylation of proteins in the synaptic plasma membranes of rat striatum. In: *Progress in Clinical and Biological Research*, Vol. 27, *Membrane Mechanisms of Drugs of Abuse*, eds: Sharp and Abood, Alan R. Liss, Inc., New York, 1979, pp 101-121.
3. Clouet, D.H. and O'Callaghan, J.P.: The role of protein kinases in opiate actions in brain. In: *Advances in Biochemical Psychopharmacology*, Vol. 20, *Neurochemical Mechanisms of Opiate and Endorphins*, eds: Loh and Ross, Raven Press, New York, 1979, pp. 281-300.
4. Billingsley, M.L., O'Callaghan, J.P. and Balaban, C.D. Pharmacologic and immunologic approaches to the problems of posttraumatic glial proliferation following CNS damage. In: *Glial-Neuronal Communication in Development and Regeneration*, NATO ASI Series H, *Cell Biology*, Vol. II, Eds. H.H. Althaus and W. Seifert, Springer-Verlag, New York, pp. 607-628, 1987.

5. O'Callaghan, J.P.: Neurotypic and gliotypic proteins as biochemical markers of neurotoxicity. *Neurotoxicology and Teratology* 10: 445-452, 1988.
6. O'Callaghan, J.P. and Miller, D.B.: Assessment of chemically-induced alterations in brain development using assays of neuron- and glia-localized proteins. *Neurotoxicology* 10: 393-406, 1989.
7. McEwen, B.S., Brinton, R.E., Chao, H.M., Coirini, H., Gannon, M.N., Gould, E., O'Callaghan, J.P., Spencer, R., Sakai, R., Woolley, C.: The Hippocampus: A site for modulatory interactions between steroid hormones, neurotransmitters and neuropeptides. In: *Neuroendocrine Perspectives, Volume VIII*, Eugene E. Mueller & R. M. MacLeod, Eds., pp. 93-131, Springer-Verlag, New York, 1990.
8. O'Callaghan, J.P.: The Use of Glial Fibrillary Acidic Protein in First Tier Assessments of Neurotoxicity. *J. Amer. Coll. Toxicol.* 10: 719-726, 1991.
9. O'Callaghan, J.P.: Neurotypic and gliotypic proteins as biochemical indicators of neurotoxicity. In: *Neurotoxicology*, M.B. Abou-Donia, ed., pp. 61-78, CRC Press, Boca Raton, 1992.
10. O'Callaghan, J.P.: Assessment of neurotoxicity using assays of neuron- and glia-localized proteins: Chronology and Critique. In: *Target Organ Toxicology Series: Neurotoxicology*, Hugh Tilson and Clifford Mitchell, Eds., Raven Press, Ltd., New York, pp. 83-100, 1992.
11. O'Callaghan, J.P. and Jensen, K.F.: Enhanced expression of glial fibrillary acidic protein and the cupric silver degeneration reaction can be used as sensitive and early indicators of neurotoxicity. *Neurotoxicol.* 13: 113-122, 1992.
12. Breese, G.R., Criswell, H.E., Duncan, G.E., Johnson, K.B., Simson, P.E., Mueller, R.A., Jensen, K.F. and O'Callaghan, J.P.: Investigations of adaptive changes associated with lesioning dopaminergic neurons with 6-hydroxydopamine. In: *Progress in Parkinson's Disease Research-2*, F. Hefti and W.J. Weiner, Eds., Futura Publishing Co., Inc., Mount Kisco, NY, pp. 259-274, 1992.
13. O'Callaghan, J.P. and Miller, D.B.: Quantification of reactive gliosis as an approach to neurotoxicity assessment. In: *Assessing Neurotoxicity of Drugs of Abuse*. Erinoff, L., Ed., National Institute on Drug Abuse Monograph 136, pp. 188-212, Washington, D.C., U.S. Government Printing Office, 1993.
14. Jensen, K.F., Olin, J.K., Haykal-Coates, N., O'Callaghan, J.P., Miller, D.B. and de Olmos, J.: Mapping toxicant-induced nervous system damage with a cupric silver stain. A quantitative analysis of neural degeneration induced by 3,4-methylenedioxymethamphetamine (MDMA). In: *Assessing Neurotoxicity of Drugs of Abuse*. Erinoff, L., Ed., National Institute on Drug Abuse Monograph 136, pp 133-154, Washington, D.C., U.S. Government Printing Office, 1993.
15. O'Callaghan, J.P.: Quantitative features of reactive gliosis following toxicant-induced damage of the CNS. *Ann. NY Acad. Sci.* 679: 195-210, 1993.
16. Billingsley, M.L. and O'Callaghan, J.P.: Molecular Neurotoxicology. In: *Principles of Neurotoxicology*. Chang, L.W. Ed., Marcel Dekker, Inc., New York, pp 551-562, 1994.
17. Breese, G.R., Criswell, H.E., Johnson, K.B., O'Callaghan, J.P., Duncan, G.E., Jensen, K.F., Simson, P.E. and Mueller, R.A.: Neonatal destruction of dopaminergic neurons. *Neurotoxicology* 15: 149-160, 1994.
18. O'Callaghan, J.P.: Biochemical analysis of glial fibrillary acidic protein as a quantitative approach to neurotoxicity assessment: advantages, disadvantages and application to the

- assessment of NMDA receptor antagonist-induced neurotoxicity. *Psychopharmacol. Bull.* 30: 549-554, 1994.
19. O'Callaghan, J.P.: MDMA Neurotoxicity: Commentary on article by Ricaurte and colleagues. *Bull. of the Multidisciplinary Assoc. for Psychedelic Studies* 6: 13, 1995.
 20. O'Callaghan, J.P., Jensen, K.F. and Miller, D.B.: Quantitative aspects of drug and toxicant-induced astrogliosis. *Neurochem. Int.* 26: 115-124, 1995.
 21. Ali, S.F. and O'Callaghan, J.P.: Preface: Cellular and Molecular Mechanisms of Drugs of Abuse. Cocaine and Methamphetamine. *Mol. Neurobiol.* 11: vii, 1995.
 22. Miller, D.B. and O'Callaghan, J.P.: The role of temperature, stress, and other factors in the neurotoxicity of the substituted amphetamines: 3,4-methylenedioxymethamphetamine and fenfluramine. *Mol. Neurobiol.* 11: 177-192, 1995.
 23. Martin, P.M. and O'Callaghan, J.P.: Biochemical immunohistology. In: *Central Nervous System Trauma: Research Techniques*, S.T. Ohnishi and T. Ohnishi, eds., CRC Press, Boca Raton, FL, pp. 509-516, 1995.
 24. Miller, D.B., Bartke, A. and O'Callaghan, J.P.: Increased glial fibrillary acidic protein (GFAP) levels in the brains of transgenic mice expressing the bovine growth hormone (bGH) gene. *Experimental Gerontology* 30: 383-400, 1995.
 25. Martin, P.M. and O'Callaghan, J.P.: Gene expression in astrocytes after neural injury. In: *The Role of Glia in Neurotoxicity*, M. Aschner and H.K. Kimmelberg, Eds. CRC Press, Boca Raton, FL, pp. 285-310, 1996.
 26. Miller, D.B. and O'Callaghan, J.P.: Neurotoxicity of d-amphetamine in the C57BL/6J and CD-1 mouse: Interactions with stress and the adrenal system. *Ann. New York Acad. Sci.* 801: 148-167, 1996.
 27. O'Callaghan, J.P., Rogers, T.S., Rodman, L.E. and Page, J.G.: Acute and chronic administration of ibogaine to the rat results in astrogliosis that is not confined to the cerebellar vermis. *Ann. NY Acad. Sci.* 801:205-216, 1996.
 28. O'Callaghan, J.P.: Reactive gliosis as an indicator of neurotoxicity. In: *Obesity Management and Redux™*, S. Nicolaïdis, ed. Academic Press, London, pp. 43-47, 1997.
 29. da Cruz e Silva, E.F. and O'Callaghan, J.P.: Phosphoprotein phosphatases as potential mediators of neurotoxicity. In: *Comprehensive Toxicology*, Vol. 11, Nervous System and Behavioral Toxicology, Sipes, G., McQueen, C.A and Gandolfi, A.J., eds. Elsevier Science, London, 1997, pp 181-200.
 30. Miller, D.B. and O'Callaghan, J.P.: Stress and adrenal system interactions with the neurotoxicity of d-amphetamine in the female C57BL/6J mouse. *Arquivos de Medicina* 12: 123-129, 1998.
 31. O'Callaghan, J.P.: Defining Neurotoxicity: Lessons from MDMA In: *Ecstasy: The Complete Guide. A Comprehensive Look at the Risks and Benefits of MDMA*. Inner Traditions, Rochester, VT , pp. 205-215, 2002.
 32. O'Callaghan, J.P., Miller, D.B. and Pennypacker, K.R.: Chronic dopaminergic signaling in the basal ganglia: A damage perspective on kinases and fos-related antigens. *J. Addiction Biol.* 5: 369-376, 2000.
 33. Miller, D.B., O'Callaghan, J.P. and Johnson, E. A.: Prior exposure to a behaviorally sensitizing regimen of d-methamphetamine does not alter the striatal dopaminergic damage induced by a neurotoxic regimen. *Addiction Biol.* 5: 361-367, 2000.

34. Rowland, A.S., Umbach, D.M., O'Callaghan, J.P., Miller, D.B. and Dunnick, J.K.: Public Health and Toxicological Issues Concerning Stimulant Treatment of ADHD. In: Attention Deficit Hyperactivity Disorder: State of the Science•Best Practices. Peter M. Jensen & James R. Cooper, eds., Civic Research Institute, Inc., Kingston, NJ 2002, pp. 10-1 – 10-16.
35. Little, A.R., Jr. and O'Callaghan, J.P.: The astrocyte response to neural injury: a review and reconsideration of key features. In: Site-Selective Neurotoxicity. David Lester, William Slikker & Philip Lazarovici, eds. Taylor and Francis Publishers, London, 2002, pp. 233-265.
36. Miller, D.B., O'Callaghan, J.P. and Ali, S.F.: Age as a susceptibility factor in the striatal dopaminergic neurotoxicity observed in the mouse following substituted amphetamine exposure. *Ann. NY Acad. Sci.* 914: 194-207, 2000.
37. Hebert, M.A. and O'Callaghan, J.P.: Protein phosphorylation cascades associated with methamphetamine-induced glial activation. *Ann. NY Acad. Sci.* 914: 238-262, 2000.
38. O'Callaghan, J.P. and Miller, D.B.: Neurotoxic effects of substituted amphetamines in rats and mice: Challenges to the current dogma. In: Handbook of Neurotoxicity, Vol. 2, E. J. Massaro, ed., Humana Press, Totowa, NJ, pp. 269-301, 2002.
39. O'Callaghan, J.P.: Measurement of glial fibrillary acidic protein. In: Current Protocols in Toxicology. L.G. Costa, Ed., John Wiley & Sons, New York, pp. 12.81.1-12.8.12, 2002.
40. Tiffany-Castiglioni, E., Guerri, C., Aschner, M., Matsushima, G.K., O'Callaghan, J.P. and Streit, W.J.: Roles of glia in developmental neurotoxicity: Session VI summary and research needs. *Neurotoxicology* 22: 567-573, 2001.
41. Miller, D.B. and O'Callaghan, J.P.: Neuroendocrine aspects of the response to stress. *Metabolism* 51: 5-10, 2002.
42. O'Callaghan, J.P.: Neurotoxic Esterase: Not so Toxic? *Nature Genetics* 33: 437-438, 2003.
43. Miller, D.B. and O'Callaghan, J.P.: Aging and stress: Implications for hippocampal structure and function. *Metabolism* 52: 17-21, 2003.
44. Sriram, K. and O'Callaghan, J.P.: Signaling mechanisms underlying toxicant-induced gliosis. In: The Role of Glia in Neurotoxicity", Second Edition, Michael Aschner and Lucio G. Costa, eds, CRC Press, Boca Raton, FL, pp. 141-171, 2005.
45. Bowyer, J.F., Harris, A., Jakab, R., Delongchamp, R., Miller, D. and O'Callaghan, J.: cDNA array analysis of the changes in gene expression specifically produced by neurotoxic doses of amphetamine: Not quite mission impossible. In: Emerging Technologies in Neurotoxicology: Session III Summary and Research Needs. G. Jean Harry, Ed., *Neurotoxicology* 25: 503-506, 2004.
46. Miller, D.B. and O'Callaghan, J.P.: Depression, Cytokines and Glial Function. *Metabolism* 54: 33-88, 2005.
47. Miller, D.B. and O'Callaghan, J.P.: Aging, Stress and the Hippocampus. *Aging Res. Rev.* 4: 123-140, 2005.
48. Berman, J.W., Carson, M.J., Chang, L., Cox, B.M., Fox, H.S., Gonzalez, R.G., Hanson, G.R., Hauser, K.F., Ho, W.-A., Hong, J.-S., Major, E.O., Marago, W.F., Maslia, E., McArthur, J.C., Miller, D.B., Nath, A., O'Callaghan, J.P., Persidky, Y., Power, C., Roger, J.J., Royal, W.: NeurAIDS, Drug Abuse, and Inflammation: Building Collaborative Research Activities. *J. Neuroimmune Pharm.* 1: 351-399, 2006.
49. Miller, D.B. and O'Callaghan, J.P.: Do Early Life Insults Contribute to the Development

- of the Late Life Diseases of Parkinson's and Alzheimer's? *Metabolism* 57: S44-49, 2008.
50. O'Callaghan, J.P., Sriram, K., and Miller, D.B.: Defining "Neuroinflammation": Lessons from MPTP- and Methamphetamine-Induced Neurotoxicity. *Annal. NY Acad. Sci.* 1139: 318-330, 2008.
 51. Binns, J.H., Barlow, C., Bloom, F.E., Clauw, D.J., Golomb, B.A., Graves, J.C., Hardie, A., Knox, M.L., Meggs, W.J., Nettlemen, M. D., O'Callaghan, J.P., Smithson, S., Steele, L., White, R.F.: Gulf War Illness and the Health of Gulf War Veterans: Scientific Findings and Recommendations. Research Advisory Committee on Gulf War Veterans' Illnesses. Gov. Printing Office, November 2008.
 52. Da Cruz e Silva, E.F. and O'Callaghan, J.P.: Protein phosphatase 1 as a potential mediator of aluminum neurotoxicity. In: *Comprehensive Toxicology*, Vol. 13, Martin Philbert, ed. Elsevier, 2010.
 53. Zhang, D., Hu, X., Li, Q., O'Callaghan, J.P. and Hong, J.-S.: Astrogliosis in CNS pathologies: Is there a role for microglia. *Molecular Neurobiol.* 41: 232-241, 2010.
 54. Turner, R.C., Lucke-Wold, B., Miller, D.B., O'Callaghan, J.P., Rosen, C.L. and Huber, J.D. Neuropoietic cytokines and neural injury: alterations in JAK2/STAT3 signaling associated with aging. In: "Neurological Disorders-New Research", C.E. Thomas and J.R. Moore, Eds., Nova Science Publishers, Hauppauge NY, pp 27-48, 2012.
 55. Binns, J.H., Bloom, F.E., Bunker, J.A., Crawford, F., Golomb, B.A., Graves, J.C., Klimas, N., O'Callaghan, J.P., Ondra, S.L., Philbert, M.A., Steele, L., White, R.F.: Gulf War Illness and the Health of Gulf War Veterans: Research Update and Recommendations, 2009-2013. Gov. Printing Office, 2014

Internet highlights:

Global Medical Discovery: STAT3 PLOSone paper highlight:

<https://globalmedicaldiscovery.com/key-scientific-articles/early-activation-stat3-regulates-reactive-astrogliosis-induced-diverse-forms-neurotoxicity/>

Congressionally Directed Medical Research Program Gulf War Illness grant highlight:

http://cdmrp.army.mil/gwirp/research_highlights/14Lasley_OCallaghan_highlight.shtml

Corrigendum:

J. Neurosci. Methods 43: 231, 1992.

Letter to the Editor:

Goldey, E.S., O'Callaghan, J.P., Stanton, M.E. and Crofton, K.M. Re: Dose as central variable in toxicology. *Fund. App. Toxicol.* 24: 290, 1995.

Centers for Disease Control and Prevention-NIOSH Reports:

NIOSH Alert: Hazardous Drugs-update April, 2010-2011

Veterans Administration:

Gulf War Research Strategic Plan (Draft)- December, 2011

U.S. Environmental Protection Agency Reports:

1. Proposed Preregulatory Investigation: Paints and Allied Products. Chemical Control Division, Office of Toxic Substances, OPTS, 1981.
2. An evaluation of nervous-system specific proteins as biochemical indicators of neurotoxicity. New Funding Initiative for Office of Pesticides and Toxic Substances, 1983.
3. Nervous-system-specific proteins as biochemical indicators of neurotoxicity. Major ORD Accomplishment Report, Office of Research and Development, 1985.
4. Draft Report on Biomarker Research in Neurotoxicology. Office of Health Research, ORD, 1987.
5. Use of monoclonal antibodies in neurotoxicological research. Administrator Initiative Item, 1987.
6. Draft Guideline: Use of Assays of GFAP in the Assessment of Developmental Neurotoxicity. OPTS, 1988.
7. Draft Guideline: Use of Assays of GFAP in Neurotoxicity Risk Assessment. OPTS, 1989.
8. Major Milestone, Superfund Research: Report on Characterization of Novel Nervous System Specific Proteins, 1989.
9. Progress Report: NIDA/EPA Interagency Agreement RA-ND-89-4, "Interdisciplinary Assessment of the Neurotoxic Effects of MDMA, MPTP, Cocaine and THC" (10/89).
10. Deliverable # 3121: Potential Biomarkers for Neurotoxic Effects. Office of Health Research, ORD (8/90).
11. Contributor: ORD Health Biomarkers Program; Research Strategy Document. Office of Research and Development EPA/600/9-91/009, April 1991.
12. Progress Report: NIDA/EPA Interagency Agreement 1-Y01 DA 30063, "Neurotoxicity of Ibogaine" (12/93).